During the past decade, Tudogyogyintezet Torokbalint conducted 41 clinical trials. In the 10-year time frame, 41 clinical trials started and 15 clinical trials were completed, i.e. on average, 36.6% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 9 clinical trials were completed. i.e. 47.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tudogyogyintezet Torokbalint" #1 sponsor was "Hoffmann-La Roche" with 14 trials, followed by "Janssen Research & Development, LLC" with 4 trials sponsored, "Pfizer" with 4 trials sponsored, "Amgen" with 3 trials sponsored and "Daiichi Sankyo, Inc." with 3 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tudogyogyintezet Torokbalint" #1 collaborator was "AstraZeneca" with 3 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Analytical Biochemical Laboratory" with 1 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Tudogyogyintezet Torokbalint" are "Non-Small Cell Lung Cancer" (9 trials), "Carcinoma, Non-Small-Cell Lung" (6 trials), "Small Cell Lung Cancer" (4 trials), "Idiopathic Pulmonary Fibrosis" (3 trials) and "Non-small Cell Lung Cancer" (3 trials). Many other conditions were trialed in "Tudogyogyintezet Torokbalint" in a lesser frequency.

Most popular intervention types in "Tudogyogyintezet Torokbalint" are "Drug" (49 trials), "Biological" (4 trials) and "Other" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Atezolizumab" (9 trials), "Carboplatin" (9 trials), "Docetaxel" (7 trials) and "Pemetrexed" (5 trials). Other intervention names were less common.

The vast majority of trials in "Tudogyogyintezet Torokbalint" are 50 trials for "All" genders.

Currently, there are NaN active trials in "Tudogyogyintezet Torokbalint". undefined are not yet recruiting, 8 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Tudogyogyintezet Torokbalint, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Tudogyogyintezet Torokbalint, 2 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 39 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".